Strengthening Diversity, Equity, and Inclusion in Pharma

The pharma industry is aware that it needs to improve the representation of women and minority communities in its businesses. The benefits of diverse teams are clear, yet it isn’t an easy road. How can companies create an environment where people feel safe, thrive, and attract the best?

Approaching Diversity and Inclusion as part of a wider Sustainability / Environment, Social, and Governance (ESG) performance is an essential indicator of pharma companies' commitment to driving I&D for a more diverse and successful workplace, which ultimately also ensures to better serve patients around the world.

Content provided by our supplier

Dr. Reddy's Laboratories SA

CH
2015

On CPHI since
3

Certificates
5000+

Employees

Company types

Generics/Biosimilars Manufacturer

Primary activities

API Producer

Chemical Development

Generic APIs producer

Pharmaceutical Company (generic finished products)

Other Content from Dr. Reddy's Laboratories SA (4)

News Pharma Explained: Active Pharmaceutical Ingredients

What are APIs? As the name suggests, Active Pharmaceutical Ingredients (APIs) are the heart of any dosage form, whether they are oral, injectable or inhaled, and are absolutely essential to the development of a formulated product.

11 Mar 2021
Brochure Dabired (Dabigatran Pellets)

Dabired is ready to fill Dabigatran Etexilate Mesylate 42.04% w/w pellets which are designed to integrate seamlessly into your encapsulation process.
Whitepaper Sacubitril/Valsartan (LCZ696) Whitepaper

This whitepaper outlines Dr. Reddy’s development and characterization approach for the API and how formulation success and early market reach can be facilitated.
Video Innovation Across Borders: How Pharma and innovators are fighting back against COVID-19 and ways forward

A global pandemic demands a fast response. The research-based pharmaceutical industry is working upstream at extraordinary speed to develop a safe and effective vaccine for COVID19. Pharmaceutical companies around the globe are joining forces and speeding up the process by conducting phases and development in parallel and forging new partnerships and collaboration. The pharmaceutical and life science industry has faced the need to leverage science and technology, developed pre and during the pandemic. Firms are coming up with new ways to maintain production despite disrupted supply chains, or they are mobilizing to design new products as demand for existing products collapses. This discussion will examine how the COVID-19 pandemic is driving pharma and life science companies to collaborate, innovate and prepare for an uncertain future. This webinar was originally aired as part of the CPHI Festival of Pharma.